• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$16.85
+0 (0.00%)

This chart shows the closing price for VECT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New VectivBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VECT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VECT

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for VectivBio in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $16.85.

This chart shows the closing price for VECT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in VectivBio. This rating has held steady since May 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/15/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/13/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/12/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/6/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/23/2023SVB SecuritiesDowngradeOutperform ➝ Market Perform
5/22/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral
4/20/2023Piper SandlerBoost TargetOverweight$23.00 ➝ $25.00
12/13/2022Jefferies Financial GroupInitiated CoverageBuy$18.00
10/13/2022Leerink PartnersBoost TargetOutperform$28.00 ➝ $30.00
7/1/2022Piper SandlerInitiated CoverageOverweight$23.00
5/4/2021Lifesci CapitalReiterated RatingOutperform
5/4/2021Leerink PartnersInitiated CoverageOutperform$28.00
5/4/2021Credit Suisse GroupInitiated CoverageOutperform$24.00
5/4/2021Bank of AmericaInitiated CoverageBuy$19.00
(Data available from 12/6/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/10/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/7/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/6/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
VectivBio logo
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
Read More

Today's Range

Now: $16.85
Low: $16.85
High: $16.85

50 Day Range

MA: $16.85
Low: $16.85
High: $16.85

52 Week Range

Now: $16.85
Low: $4.25
High: $16.98

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of VectivBio?

The following equities research analysts have issued research reports on VectivBio in the last twelve months:
View the latest analyst ratings for VECT.

What is the current price target for VectivBio?

0 Wall Street analysts have set twelve-month price targets for VectivBio in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for VectivBio in the next year.
View the latest price targets for VECT.

What is the current consensus analyst rating for VectivBio?

VectivBio currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for VECT.

What other companies compete with VectivBio?

How do I contact VectivBio's investor relations team?

The company's listed phone number is 41-61-551-3030 and its investor relations email address is [email protected]. The official website for VectivBio is vectivbio.com. Learn More about contacing VectivBio investor relations.